Case-Based Roundtable Meetings Spotlight: February 1, 2022
Roundtable Discussion: Dowlati Debates the Role of Osimertinib in Adjuvant Treatment of NSCLC
February 3rd 2022During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, and participants discussed the challenges of molecular testing and how to use test results to introduce targeted treatments for patients with non–small cell lung cancer.
Roundtable Discussion: Kundranda and Participants Review First-line and Later-line Therapies in CRC
February 1st 2022During a Targeted Oncology case-based roundtable event, Madappa Kundranda, MD, PhD, and participants discussed the case of a patient with recently diagnosed, unresectable colorectal cancer.
Roundtable Discussion: Aghalar and Vaena Look at The role of Cabazitaxel in CRPC
February 1st 2022During a Targeted Oncology live event, Jahan Aghalar, MD, and Daniel Vaena, MD, discussed the results of trials of cabazitaxel in patients with castration-resistant prostate cancer and how to manage toxicity of the therapy.
Lunning Discusses Second-Line Treatments in Diffuse Large B-Cell Lymphoma
January 31st 2022During a Targeted Oncology case-based roundtable event, Matthew A. Lunning, DO, discussed the results of the L-MIND study of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.
Gadgeel Discusses Therapies for Patients With NSCLC and CNS Metastases
January 29th 2022During a Targeted Oncology case-based roundtable event, Shirish M Gadgeel, MD, discussed the results of the ALEX, ALTA-1L, and CROWN studies of immune checkpoint inhibitors in non–squamous non–small cell lung cancer.
Roundtable Discussion: Integrating New Approaches for Advanced Relapsed/Refractory RCC Into Practice
January 28th 2022During a Targeted Oncology case-based roundtable event, Sumanta Kumar Pal, David I. Quinn, MD, MBBS, PhD, and participants discussed frontline therapy options for a patient with metastatic relapsed/refractory renal cell carcinoma.
